Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Joseph Tripodi, Douglas Tremblay, MD, Ronald Hoffman, MD, Umut Ozbek, PhD, John Mascarenhas, MD, Marina Kremyanskaya, Vesna Najfeld, PhD

Blood (2019) 134 (Supplement_1): 1687.

https://doi.org/10.1182/blood-2019-128948

Published: 2019

Journal Articles

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Bridget Marcellino, MD PhD, Joseph Tripodi, Michal Bar-Natan, MD, Harry Fruchtman, Noushin Farnoud, PhD, Min Lu, PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Raajit K. Rampal, MD PhD, John Mascarenhas, MD, Vesna Najfeld, PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4207.

https://doi.org/10.1182/blood-2019-129565

Published: 2019

Journal Articles

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

Zachary D. Epstein-Peterson, MD, Joseph Tripodi, Maria E Arcila, MD, Filiz Sen, MD, Vesna Najfeld, PhD, John Mascarenhas, MD, Ronald Hoffman, MD, Rajit K. Rampal, MD, PhD

Blood (2019) 134 (Supplement_1): 4173.

https://doi.org/10.1182/blood-2019-125379

Published: 2019

Journal Articles

Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia

Anne S. Renteria, MD, Sangeetha Venugopal, MD, Bridget Marcellino, MD PhD, Alla Keyzner, MD, Marina Kremyanskaya, MD PhD, Vesna Najfeld, PhD, John Mascarenhas, MD

Blood (2018) 132 (Supplement 1): 5158.

https://doi.org/10.1182/blood-2018-99-115634

Published: 2018

Journal Articles

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Blood (2018) 132 (Supplement 1): 577.

https://doi.org/10.1182/blood-2018-99-111946

Published: 2018

Journal Articles

Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Blood (2018) 132 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2018-99-111935

Published: 2018

Journal Articles

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Blood (2018) 132 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2018-99-111929

Published: 2018

Journal Articles

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells

Xiaoli Wang, PhD, Cing Siang Hu, Joseph Tripodi, Vesna Najfeld, PhD, Bruce Petersen, MD, Raajit K. Rampal, MD PhD, Noushin Farnoud, Christopher Famulare, MS, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2018) 132 (Supplement 1): 101.

https://doi.org/10.1182/blood-2018-99-117348

Published: 2018

Journal Articles

Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 321.

https://doi.org/10.1182/blood.V130.Suppl_1.321.321

Published: 2017

Journal Articles

Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 4206.

https://doi.org/10.1182/blood.V130.Suppl_1.4206.4206

Published: 2017

Journal Articles

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Both Short and Long Term Hematopoietic Stem Cells

Xiaoli Wang, PhD, Cing Siang Hu, Raajit K. Rampal, MD PhD, Joseph Tripodi, Vesna Najfeld, PhD, Bruce Petersen, MD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2017) 130 (Supplement 1): 2943.

https://doi.org/10.1182/blood.V130.Suppl_1.2943.2943

Published: 2017

Journal Articles

Advanced Forms of the Myeloproliferative Neoplasms Are Associated with Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression

Bridget Marcellino, MD PhD, Joseph Tripodi, Min Lu, PhDMD, Heidi Kosiorek, MS, John Mascarenhas, MD, Raajit K. Rampal, MD PhD, Amylou Constance Dueck, PhD, Ronald Hoffman, MD, Vesna Najfeld, PhD

Blood (2017) 130 (Supplement 1): 204.

https://doi.org/10.1182/blood.V130.Suppl_1.204.204

Published: 2017

Journal Articles

Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression

Vesna Najfeld, PhD, Joseph Tripodi, MS, Xiaoli Wang, MD PhD, Myron Schwartz, MD, Marina Kremyanskaya, MDPhD, Edward Cytryn, Sharon Zirkiev, Raajit K. Rampal, MD, PhD, John O Mascarenhas, MD MS, Ronald Hoffman, MD

Blood (2014) 124 (21): 1871.

https://doi.org/10.1182/blood.V124.21.1871.1871

Published: 2014

Journal Articles

Characterization Of Splenic Fibroblasts From Patients With Myelofibrosis

Xiaoli Wang, Joseph Tripodi, MS, Vesna Najfeld, PhD, Min Lu, PhD, Ronald Hoffman, MD

Blood (2013) 122 (21): 4107.

https://doi.org/10.1182/blood.V122.21.4107.4107

Published: 2013

Journal Articles

Peripheral Blood Karyotyping Is Superior To Bone Marrow and Identifies Most Frequent Structural Chromosomal Rearrangements In Myelofibrosis

Vesna Najfeld, PhD, Joseph Tripodi, MS, Marina Kremanskaya, MD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2013) 122 (21): 3727.

https://doi.org/10.1182/blood.V122.21.3727.3727

Published: 2013

Journal Articles

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Lewis R. Silverman, MD, Amit Verma, MD, Rosalie Odchimar-Reissig, RN, Eric J. Feldman, MD, Shyamala C. Navada, MD, Erin P Demakos, RN, Maria R. Baer, MD, Vesna Najfeld, PhD, Joseph A Sparano, MD, Richard Piekarz, MD, PhD

Blood (2013) 122 (21): 386.

https://doi.org/10.1182/blood.V122.21.386.386

Published: 2013

Journal Articles

Patients with Newly Diagnosed Multiple Myeloma and a Gain of the Long Arms of Chromosome 1 Have Inferior Outcomes, Including Early Onset Extramedullary Disease, Despite the Use of Novel Triplet Regimens

Noa Biran, MD, Vesna Najfeld, PhD, Emily Bagiella, Sundar Jagannath, MD, Ajai Chari, MD

Blood (2012) 120 (21): 4996.

https://doi.org/10.1182/blood.V120.21.4996.4996

Published: 2012

Journal Articles

Chromosomal and FISH Study of 286 Patients with Primary Myelofibrosis (PMF) Reveals Cryptic Abnormalities and Identifies Lesions Associated with Favorable Prognosis and Disease Progression,

Vesna Najfeld, PhD, John Mascarenhas, MD, Steven Fruchtman, MD, Samuel Cytryn, Marina Kremyanskaya, MD, Joseph Tripodi, MS, Ronald Hoffman, MD

Blood (2011) 118 (21): 3526.

https://doi.org/10.1182/blood.V118.21.3526.3526

Published: 2011

Journal Articles

Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis

John Mascarenhas, MD, Alice Mercado, RN, Amelyn Rodriguez, BSN, RN, OCN, Min Lu, PhD, Carla Kalvin, Xiaochun Li, PhD, Bruce Petersen, MD, Vesna Najfeld, PhD, Judith D. Goldberg, Sc.D., Ronald Hoffman, MD

Blood (2011) 118 (21): 794.

https://doi.org/10.1182/blood.V118.21.794.794

Published: 2011

Journal Articles

Treatment with Nutlin-3, a Small-Molecule Antagonist of MDM2, in Combination with Low Doses of Pegylated Interferon Alpha 2a Targets Hematopoietic Progenitor Cells From Polycythemia Vera (PV) Patients

Min Lu, PhD, Joseph Tripodi, MS, Yan Li, Xiaoli Wang, MD, PhD, Vesna Najfeld, PhD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2011) 118 (21): 796.

https://doi.org/10.1182/blood.V118.21.796.796

Published: 2011

NARROW

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Both Short and Long Term Hematopoietic Stem Cells

Advanced Forms of the Myeloproliferative Neoplasms Are Associated with Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression

Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression

Characterization Of Splenic Fibroblasts From Patients With Myelofibrosis

Peripheral Blood Karyotyping Is Superior To Bone Marrow and Identifies Most Frequent Structural Chromosomal Rearrangements In Myelofibrosis

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Patients with Newly Diagnosed Multiple Myeloma and a Gain of the Long Arms of Chromosome 1 Have Inferior Outcomes, Including Early Onset Extramedullary Disease, Despite the Use of Novel Triplet Regimens

Chromosomal and FISH Study of 286 Patients with Primary Myelofibrosis (PMF) Reveals Cryptic Abnormalities and Identifies Lesions Associated with Favorable Prognosis and Disease Progression,

Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis

Treatment with Nutlin-3, a Small-Molecule Antagonist of MDM2, in Combination with Low Doses of Pegylated Interferon Alpha 2a Targets Hematopoietic Progenitor Cells From Polycythemia Vera (PV) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only